×
About 778 results

ALLMedicine™ Antithrombin Iii Center

Research & Reviews  281 results

Antithrombin III Deficiency
https://emedicine.medscape.com/article/954688-overview

Jan 10th, 2022 - Practice Essentials Antithrombin III (ATIII) is a nonvitamin K-dependent protease that inhibits coagulation by neutralizing the enzymatic activity of thrombin (factors IIa, IXa, Xa). Antithrombin III activity is markedly potentiated by heparin, th...

Antithrombin III Deficiency
http://emedicine.medscape.com/article/954688-overview

Jan 10th, 2022 - Practice Essentials Antithrombin III (ATIII) is a nonvitamin K-dependent protease that inhibits coagulation by neutralizing the enzymatic activity of thrombin (factors IIa, IXa, Xa). Antithrombin III activity is markedly potentiated by heparin, th...

Prosthetic Heart Valves Medication
https://emedicine.medscape.com/article/780702-medication&

Jan 3rd, 2022 - Medication Summary Antibiotics, vasodilators, inotropic agents, and anticoagulants are the therapeutic agents most commonly used in heart-valve complications. Next: Vasodilators Class Summary A significant portion of cardiac output is regurgitated...

Antithrombin III in Infectious Disease Caused by COVID-19
https://clinicaltrials.gov/ct2/show/NCT04899232

Dec 21st, 2021 - The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.

Unusual pattern of thrombotic events in young adult non-critically ill patients with CO...
https://doi.org/10.1111/bjh.17986
British Journal of Haematology; Elbadry MI, Tawfeek A et. al.

Dec 11th, 2021 - In 145 previously healthy non-critically ill young adults, coronavirus disease 2019 (COVID-19)-related symptoms, risk factors for thrombosis, coagulation and inflammatory parameters were compared, with 29 patients reporting unusual thrombotic even...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  16 results

Antithrombin III in Infectious Disease Caused by COVID-19
https://clinicaltrials.gov/ct2/show/NCT04899232

Dec 21st, 2021 - The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.

Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
https://clinicaltrials.gov/ct2/show/NCT04651400

Dec 6th, 2021 - Multicentre, multinational, non-interventional, observational, retrospective, patient record study to evaluate changes in coagulation parameters in patients with severe COVID-19 infection receiving/not treatment with antithrombin (AT) III

Influence of Cardiac Implantable Electronic Devices on the Hemostatic System
https://clinicaltrials.gov/ct2/show/NCT04499612

Sep 23rd, 2021 - 250 patients of similar age, gender, and ethnicity will be divided into five groups: Group A1-3: 150 patients with indications for cardiac implantable electronic device (CIED) implantation; Group B: 50 patients with an CIED implanted 8-10 years ag...

Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients
https://clinicaltrials.gov/ct2/show/NCT04982263

Jul 29th, 2021 - In COVID-19 patients the coagulation parameters Prothrombin concentration (PC), Activated Partial Thromboplastin Time (aPTT), D Dimer, Antithrombin III (ATIII) and Fibrinogen are measured and correlation with disease severity is to be investigated

Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy
https://clinicaltrials.gov/ct2/show/NCT03255447

Jun 8th, 2021 - Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults worldwide. The majority of patients will remain stable with either complete remission or partial remission but approximately 20% will progress slowly to en...

see more →

News  11 results

Fast Five Quiz: Direct Oral Anticoagulant Therapy for Atrial Fibrillation
https://reference.medscape.com/viewarticle/924960_2

Apr 2nd, 2020 - Figure 1. The physiological cascade of blood clotting. Three of the four DOAC agents approved as anticoagulation therapy for patients with AF work through direct FXa inhibition (rivaroxaban, apixaban, edoxaban) or direct thrombin inhibition (dabig...

Fast Five Quiz: Test Your Knowledge of Venous Thromboembolism
https://reference.medscape.com/viewarticle/902400_2

Dec 3rd, 2018 - Nephrotic syndrome is one of several disease states that increase a patient's risk of developing VTE. VTE associated with nephrotic syndrome appears to be due to a hypercoagulable state resulting from urinary loss of anticoagulant proteins, togeth...

More Lab Tests Deemed Inappropriate
https://www.staging.medscape.com/viewarticle/887645

Oct 26th, 2017 -                           The American Society of Clinical Pathology (ASCP) has added five tests to the list it considers unnecessary or potentially harmful, as part of the Choosing Wisely campaign. The list has now grown to 20 recommendations. Th...

More Lab Tests Deemed Inappropriate
https://www.medscape.com/viewarticle/887645

Oct 26th, 2017 -                           The American Society of Clinical Pathology (ASCP) has added five tests to the list it considers unnecessary or potentially harmful, as part of the Choosing Wisely campaign. The list has now grown to 20 recommendations. Th...

Novel Estrogen Combination Shows Favorable Coagulation Profile
https://www.mdedge.com/obgyn/article/55699/menopause/novel-estrogen-combination-shows-favorable-coagulation-profile
Bruce Jancin

Aug 17th, 2012 - HOUSTON – The novel investigational tissue selective estrogen complex comprising bazedoxifene plus conjugated estrogens displayed an overall favorable coagulation profile in a pooled analysis of three randomized, placebo-controlled, double-blind,.

see more →